Dr. Epperla Discusses the Current Treatment of MCL

Narendranath Epperla, MBBS, MS
Published: Wednesday, Oct 18, 2017



Narendranath Epperla, MBBS, MS, hematologist, The Ohio State University (OSU) Comprehensive Cancer Center, assistant professor in internal medicine, OSU, discusses the current treatment landscape of patients with mantle cell lymphoma (MCL).

Upfront treatment for MCL continues to be induction therapy followed by autologous stem cell transplant, says Epperla. This is based on the long term follow-up data from the NORDIC trial.

In the relapsed/refractory setting, there are many agents to choose from—BTK inhibitors, PI3-kinase inhibitors, and immunomodulatory agents. Epperla says these agents can be used in various combinations.
 
SELECTED
LANGUAGE


Narendranath Epperla, MBBS, MS, hematologist, The Ohio State University (OSU) Comprehensive Cancer Center, assistant professor in internal medicine, OSU, discusses the current treatment landscape of patients with mantle cell lymphoma (MCL).

Upfront treatment for MCL continues to be induction therapy followed by autologous stem cell transplant, says Epperla. This is based on the long term follow-up data from the NORDIC trial.

In the relapsed/refractory setting, there are many agents to choose from—BTK inhibitors, PI3-kinase inhibitors, and immunomodulatory agents. Epperla says these agents can be used in various combinations.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x